36 related articles for article (PubMed ID: 23186591)
1. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
Zhang C; Ke W; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Drug Des Devel Ther; 2016; 10():897-910. PubMed ID: 27041994
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
[TBL] [Abstract][Full Text] [Related]
3. 7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Hayashi S; Higashi-Kuwata N; Das D; Tomaya K; Yamada K; Murakami S; Venzon DJ; Hattori SI; Isogawa M; Sarafianos SG; Mitsuya H; Tanaka Y
Antiviral Res; 2020 Apr; 176():104744. PubMed ID: 32084506
[TBL] [Abstract][Full Text] [Related]
4. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.
Ide T; Sata M; Chayama K; Shindo M; Toyota J; Mochida S; Tomita E; Kumada H; Yamada G; Yatsuhashi H; Hayashi N; Ishikawa H; Seriu T; Omata M
Hepatol Int; 2010 Jul; 4(3):594-600. PubMed ID: 21063482
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective.
Tsai N; Jeffers L; Cragin L; Sorensen S; Su W; Rosenblatt L; Tang H; Hebden T; Juday T
Clinicoecon Outcomes Res; 2012; 4():227-35. PubMed ID: 22977309
[TBL] [Abstract][Full Text] [Related]
7. Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients.
Baqai S; Proudfoot J; Xu R; Kane S; Clark M; Gish R
BMJ Open Gastroenterol; 2015; 2(1):e000030. PubMed ID: 26462281
[TBL] [Abstract][Full Text] [Related]
8. Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):6639-6647.
Blood Adv; 2024 Mar; 8(6):1469. PubMed ID: 38488816
[No Abstract] [Full Text] [Related]
9. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Sheng YJ; Liu JY; Tong SW; Hu HD; Zhang DZ; Hu P; Ren H
Virol J; 2011 Aug; 8():393. PubMed ID: 21824397
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
Liu F; Wang X; Wei F; Hu H; Zhang D; Hu P; Ren H
Virol J; 2014 Mar; 11():59. PubMed ID: 24673792
[TBL] [Abstract][Full Text] [Related]
11. The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
Kim JH; Kim YS; Jung YK; Kim YS; Kwon OS; Ku YS; Choi DJ; Kim JH
Hepatogastroenterology; 2013 Jun; 60(124):842-9. PubMed ID: 23186591
[TBL] [Abstract][Full Text] [Related]
12. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
13. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
15. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
